Αποτελέσματα Αναζήτησης
10 Ιουλ 2024 · Twice-yearly injections of Lenacapavir showed overwhelming efficacy for preventing HIV infections compared to standard oral preventative HIV medicines, known as pre-exposure prophylaxis (PrEP). Additional trials are ongoing in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the United States.
4 Ιαν 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
21 Ιουν 2023 · Data to inform the switch from a ritonavir-boosted protease inhibitor (PI) to dolutegravir in patients living with human immunodeficiency virus (HIV) infection who do not have genotype...
Forty years later, research has led to the approval of more than 30 antiretroviral drugs, while combination therapies have turned HIV-1 infection into a chronic, but manageable disease. Still, drug toxicity and acquired and transmitted drug resistance remain as major threats to therapy success.
17 Σεπ 2021 · Although much of this report covers advances over the last year, the IAS 2021 conference included new data on many pipeline compounds. This included studies on long-acting cabotegravir/rilpivirine, fostemsavir, lenacapavir (as treatment and PrEP), islatravir (as treatment and PrEP) and albuvirtide.
22 Ιουλ 2022 · Nature Medicine - Infrequently dosed, longer-acting antiretroviral agents are making adherence to medication easier, leading to better outcomes for those living with HIV or at risk of...
11 Δεκ 2023 · Using drug therapy to block transmission and prevent HIV, HIV pre-exposure prophylaxis (PrEP) provides a critical intervention to reduce community spread and protect those with reasons to utilize PrEP.
